A Randomised, Double-Blind, Multicentre, Superiority Placebo-Controlled, Phase III Study to Assess the Efficacy and Safety of Topical 1% SB-275833 Ointment Versus Placebo Ointment Applied Twice Daily for 5 Days in the Treatment of Adults and Paediatric Subjects With Impetigo.
Latest Information Update: 07 Sep 2023
At a glance
- Drugs Retapamulin (Primary)
- Indications Bacterial infections; Impetigo
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 16 Oct 2006 Status change
- 10 Dec 2005 New trial record.